Mouse Anti-Human Serum Amyloid a Monoclonal Antibody, Clone 4I84 (DCABH-6007) This Product Is for Research Use Only and Is Not Intended for Diagnostic Use

Total Page:16

File Type:pdf, Size:1020Kb

Mouse Anti-Human Serum Amyloid a Monoclonal Antibody, Clone 4I84 (DCABH-6007) This Product Is for Research Use Only and Is Not Intended for Diagnostic Use Mouse Anti-Human Serum Amyloid A Monoclonal Antibody, clone 4I84 (DCABH-6007) This product is for research use only and is not intended for diagnostic use. PRODUCT INFORMATION Specificity Recognize human SAA1. Do not recognize human SAA2, human SAA4, feline, canine, equine or bovine SAA. Immunogen Human serum amyloid A (SAA) Isotype IgG1 Source/Host Mouse Species Reactivity Human Clone 4I84 Purity Protein G purified Purification Purity≥ 95 % Conjugate Unconjugated Applications ELISA(Cap), ELISA(Det), LFIA We recommend the following for sandwich ELISA (Capture - Detection): DMAB8184 - DCABH-6007; DMAB8186 - DCABH-6007; DCABH-6007 - CABT-54364MH; CABT-54364MH - DCABH-6007 Epitope Recognizes aa 64-71 but also reacts with aa 28-38 indicating that the epitope may be partly conformational. Format Liquid Concentration Lot specific Size 1 mg Buffer 50 mM Na-citrate, pH 6.0, 0.9 % NaCI, 0.095 % NaN3 as a preservative. Preservative 0.095% sodium azide Storage Store at 2-8℃. 45-1 Ramsey Road, Shirley, NY 11967, USA Email: [email protected] Tel: 1-631-624-4882 Fax: 1-631-938-8221 1 © Creative Diagnostics All Rights Reserved Ship Wet ice Warnings This product is for research use only and is not intended for diagnostic use. BACKGROUND Introduction Serum amyloid A (SAA) proteins are a family of apolipoproteins associated with high-density lipoprotein (HDL) in plasma. Different isoforms of SAA are expressed constitutively (constitutive SAAs) at different levels or in response to inflammatory stimuli (acute phase SAAs). These proteins are produced predominantly by the liver. The conservation of these proteins throughout invertebrates and vertebrates suggests that SAAs play a highly essential role in all animals. Keywords SAA1;serum amyloid A1;SAA;PIG4;SAA2;TP53I4 GENE INFORMATION Gene Name SAA1 Entrez Gene ID 6288 UniProt ID P0DJI8 45-1 Ramsey Road, Shirley, NY 11967, USA Email: [email protected] Tel: 1-631-624-4882 Fax: 1-631-938-8221 2 © Creative Diagnostics All Rights Reserved.
Recommended publications
  • Influence of Serum Amyloid a (SAA1) And
    Influence of Serum Amyloid A (SAA1) and SAA2 Gene Polymorphisms on Renal Amyloidosis, and on SAA/ C-Reactive Protein Values in Patients with Familial Mediterranean Fever in the Turkish Population AYSIN BAKKALOGLU, ALI DUZOVA, SEZA OZEN, BANU BALCI, NESRIN BESBAS, REZAN TOPALOGLU, FATIH OZALTIN, and ENGIN YILMAZ ABSTRACT. Objective. To evaluate the effect of serum amyloid A (SAA) 1 and SAA2 gene polymorphisms on SAA levels and renal amyloidosis in Turkish patients with familial Mediterranean fever (FMF). Methods. SAA1 and SAA2 gene polymorphisms and SAA levels were determined in 74 patients with FMF (39 female, 35 male; median age 11.5 yrs, range 1.0–23.0). All patients were on colchicine therapy. SAA1 and SAA2 gene polymorphisms were analyzed using polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP). SAA and C-reactive protein (CRP) values were measured and SAA/CRP values were calculated. Results. The median SAA level was 75 ng/ml (range 10.2–1500). SAA1 gene polymorphisms were: α/α genotype in 23 patients (31.1%), α/ß genotype in 30 patients (40.5%), α/γ genotype in one patient (1.4 %), ß/ß genotype in 14 patients (18.9%), ß/γ genotype in 5 patients (6.8 %), and γ/γ geno- type in one patient (1.4%). Of the 23 patients who had α/α genotype for the SAA1 polymorphism, 7 patients had developed renal amyloidosis (30.4%) compared to only one patient without this geno- type (1/51; 2.0%); p < 0.001. SAA2 had no effect on renal amyloidosis. SAA1 and SAA2 genotypes had no significant effect on SAA levels.
    [Show full text]
  • Gene Expression Atlas.Pptx
    ArrayExpress Gene Expression Atlas Investigating gene expression patterns The Bioinformatics Roadshow – Rotterdam Erasmus Postgraduate school Molecular Medicine Ibrahim Emam Functional Genomics Group European Bioinformatics Institute ArrayExpress – two databases May 2, 2012 2 How we view experiments… • Given one experiment where the effect of a particular compound treatment is assayed from two different strains in four different tissue types. 02/05/2012 3 Examine profile of Saa4 in one experiment • With respect to Compound Treatment 02/05/2012 4 Examine profile of Saa4 in one experiment • With respect to Genotype 02/05/2012 5 Examine profile of Saa4 in one experiment • With respect to Organism Part (Tissue) 02/05/2012 6 Atlas construction Atlas construction - example Meta-analysis framework • For each experiment: • Identify differentially expressed genes between groups of samples • A gene is significantly differentially expressed if the combined F- statistic derived from all pairwise comparisons of the means of a gene's expression levels across factors has a sufficiently small adjusted p-value. • Score every condition/gene/experiment triplet – this score gives us the likelihood that this gene is differentially expressed for this condition in the given experiment • Correct these scores for multiple testing and make a cut-off – differentially expressed: yes/no • Repeat for all experiments 02/05/20129 Meta-analysis framework-cont’d • For every condition-gene pair count in how many experiments it is differentially expressed • The result is
    [Show full text]
  • Diversity and Complexity of the Mouse Saa1 and Saa2 Genes
    Exp. Anim. 63(1), 99–106, 2014 —Original— Diversity and Complexity of the Mouse Saa1 and Saa2 genes Masayuki MORI1), Geng TIAN1), Akira ISHIKAWA2), and Keiichi HIGUCHI1) 1)Department of Aging Biology, Institute of Pathogenesis and Disease Prevention, Shinshu University Graduate School of Medicine, 3–1–1 Asahi, Matsumoto, Nagano 390-8621, Japan 2)Laboratory of Animal Genetics, Division of Applied Genetics and Physiology, Graduate School of Bioagricultural Sciences, Nagoya University, Chikusa, Nagoya, Aichi 464-8601, Japan Abstract: Mouse strains show polymorphisms in the amino acid sequences of serum amyloid A 1 (SAA1) and serum amyloid A 2 (SAA2). Major laboratory mouse strains are classified based on the sequence as carrying the A haplotype (e.g., BALB/c) or B haplotype (e.g., SJL/J) of the Saa1 and Saa2 gene unit. We attempted to elucidate the diversity of the mouse Saa1 and Saa2 family genes at the nucleotide sequence level by a systematic survey of 6 inbred mouse strains from 4 Mus subspecies, including Mus musculus domesticus, Mus musculus musculus, Mus musculus castaneus, and Mus spretus. Saa1 and Saa2 genes were obtained from the mouse genome by PCR amplification, and each full-length nucleotide sequence was determined. We found that Mus musculus castaneus mice uniquely possess 2 divergent Saa1 genes linked on chromosome 7. Overall, the mouse strains had distinct composite patterns of amino acid substitutions at 9 positions in SAA1 and SAA2 isoforms. The mouse strains also had distinct composite patterns of 2 polymorphic upstream regulatory elements that influenced gene transcription in in vitro reporter assays. B haplotype mice were revealed to possess an LTR insertion in the downstream region of Saa1.
    [Show full text]
  • Transposable Elements As Sensors of SARS-Cov-2 Infection
    bioRxiv preprint doi: https://doi.org/10.1101/2021.02.25.432821; this version posted February 25, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Transposable elements as sensors of SARS-CoV-2 infection Matan Sorek1,2,*, Eran Meshorer1,2,* and Sharon Schlesinger3,* 1Department of Genetics, The Institute of Life Sciences, The Hebrew University of Jerusalem, Edmond J. Safra Campus, Jerusalem 9190100, Israel, 2Edmond and Lily Safra Center for Brain Sciences (ELSC), The Hebrew University of Jerusalem, Edmond J. Safra Campus, Jerusalem 9190100, Israel 3Department of Animal Sciences, Faculty of Agriculture, The Hebrew University of Jerusalem, Rehovot 7610001, Israel *Corresponding authors ([email protected]; [email protected]; [email protected]) 1 bioRxiv preprint doi: https://doi.org/10.1101/2021.02.25.432821; this version posted February 25, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Abstract Transposable elements (TEs) are induced in response to viral infections. TEs induction triggers a robust and durable interferon (IFN) response, providing a host defense mechanism. Still, the connection between SARS-CoV-2 IFN response and TEs remained unexplored. Here, we analyzed TE expression changes in response to SARS-CoV-2 infection in different human cellular models.
    [Show full text]
  • Human Serum Amyloid a (SAA)
    Clinical and Inflammation Research Area Human serum amyloid A (SAA) erum amyloid A recombinant SAA as well as purified endogenous apolipoprotein SAA has a tendency to aggregate and form oligomers Sfamily consists of (4-6). Presumably, the association of SAA molecules three members that in is mediated by amino acid residues located within human beings are cod- α-helix regions 1 (residues 2-8) and 3 (residues ed by different genes: 52-59) (4). SAA1, SAA2, and SAA4 (reviewed in 1-3). SAA1 The biological function of SAA and SAA2 are so-called acute phase isoforms. The biological function of SAA in inflammation is Their expression is in- unclear. It has been suggested that SAA is involved creased in response to in the recycling of cholesterol from damaged tissues. inflammation. SAA4 is It might play the role of a signaling molecule that a constitutive isoform, redirects HDL particles to activated macrophages the expression of which does not change during an and mediates the removal of stored cholesterol from acute-phase response. In addition, one more related them. Released cholesterol is then transferred to HDL gene (SAA3) has been identified, although this gene to be used again in the membranes of new cells that are is not expressed in human beings. required during acute inflammation and tissue repair (7). Besides that, published studies demonstrate Biochemical properties of SAA that recombinant SAA exhibits significant proinflammatory activity by inducing the synthesis SAA1 and SAA2 are synthesized in the liver of several cytokines and promoting chemotaxis for and secreted to the blood. When in the blood, monocytes and neutrophils in vitro (1, 8).
    [Show full text]
  • (SAA2) (NM 030754) Human Recombinant Protein Product Data
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for TP304977 serum amyloid A2 (SAA2) (NM_030754) Human Recombinant Protein Product data: Product Type: Recombinant Proteins Description: Recombinant protein of human serum amyloid A2 (SAA2), transcript variant 1 Species: Human Expression Host: HEK293T Tag: C-Myc/DDK Predicted MW: 13.3 kDa Concentration: >50 ug/mL as determined by microplate BCA method Purity: > 80% as determined by SDS-PAGE and Coomassie blue staining Buffer: 25 mM Tris.HCl, pH 7.3, 100 mM glycine, 10% glycerol Bioactivity: Cell treatment (PMID: 29757436) Preparation: Recombinant protein was captured through anti-DDK affinity column followed by conventional chromatography steps. Storage: Store at -80°C. Stability: Stable for 12 months from the date of receipt of the product under proper storage and handling conditions. Avoid repeated freeze-thaw cycles. RefSeq: NP_110381 Locus ID: 6289 UniProt ID: P0DJI9 RefSeq Size: 594 Cytogenetics: 11p15.1 RefSeq ORF: 366 Synonyms: SAA; SAA1 This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 2 serum amyloid A2 (SAA2) (NM_030754) Human Recombinant Protein – TP304977 Summary: This gene encodes a member of the serum amyloid A family of apolipoproteins. The encoded preproprotein is proteolytically processed to generate the mature protein. This protein is a major acute phase protein that is highly expressed in response to inflammation and tissue injury.
    [Show full text]
  • Influence of Serum Amyloid a (SAA1) and SAA2 Gene Polymorphisms On
    Influence of Serum Amyloid A (SAA1) and SAA2 Gene Polymorphisms on Renal Amyloidosis, and on SAA/ C-Reactive Protein Values in Patients with Familial Mediterranean Fever in the Turkish Population AYSIN BAKKALOGLU, ALI DUZOVA, SEZA OZEN, BANU BALCI, NESRIN BESBAS, REZAN TOPALOGLU, FATIH OZALTIN, and ENGIN YILMAZ ABSTRACT. Objective. To evaluate the effect of serum amyloid A (SAA) 1 and SAA2 gene polymorphisms on SAA levels and renal amyloidosis in Turkish patients with familial Mediterranean fever (FMF). Methods. SAA1 and SAA2 gene polymorphisms and SAA levels were determined in 74 patients with FMF (39 female, 35 male; median age 11.5 yrs, range 1.0–23.0). All patients were on colchicine therapy. SAA1 and SAA2 gene polymorphisms were analyzed using polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP). SAA and C-reactive protein (CRP) values were measured and SAA/CRP values were calculated. Results. The median SAA level was 75 ng/ml (range 10.2–1500). SAA1 gene polymorphisms were: α/α genotype in 23 patients (31.1%), α/ß genotype in 30 patients (40.5%), α/γ genotype in one patient (1.4 %), ß/ß genotype in 14 patients (18.9%), ß/γ genotype in 5 patients (6.8 %), and γ/γ geno- type in one patient (1.4%). Of the 23 patients who had α/α genotype for the SAA1 polymorphism, 7 patients had developed renal amyloidosis (30.4%) compared to only one patient without this geno- type (1/51; 2.0%); p < 0.001. SAA2 had no effect on renal amyloidosis. SAA1 and SAA2 genotypes had no significant effect on SAA levels.
    [Show full text]
  • Comparison of Gene Expression Profiles
    [CANCER RESEARCH 62, 3939–3944, July 15, 2002] Advances in Brief Comparison of Gene Expression Profiles between Hepatitis B Virus- and Hepatitis C Virus-infected Hepatocellular Carcinoma by Oligonucleotide Microarray Data on the Basis of a Supervised Learning Method1 Norio Iizuka, Masaaki Oka,2 Hisafumi Yamada-Okabe, Naohide Mori, Takao Tamesa, Toshimasa Okada, Norikazu Takemoto, Akira Tangoku, Kenji Hamada, Hironobu Nakayama, Takanobu Miyamoto, Shunji Uchimura, and Yoshihiko Hamamoto Departments of Surgery II [N. I., M. O., N. M., T. T., T. O., N. T., A. T.] and Bioregulatory Function [N. I.], Yamaguchi University School of Medicine, Yamaguchi 755-8505; Department of Computer Science and Systems Engineering, Faculty of Engineering, Yamaguchi University, Yamaguchi 755-8611 [T. M., S. U., Y. H.]; and Department of Oncology, Nippon Roche Research Center, Kanagawa 247-8530 [H. Y-O., K. H., H. N.], Japan Abstract nisms responsible for the pathogenesis of HCC differ between HBV and HCV infections. Several studies compared gene expression be- Gene expression profiles of hepatocellular carcinomas (HCCs) associ- tween nontumorous liver and HCC and revealed gene expression ated with hepatitis B virus (HBV) and hepatitis C virus (HCV) were patterns that are rather specific to HCC (10–14). However, there is analyzed and compared. Oligonucleotide microarrays containing >6000 genes and subsequent gene selection by a supervised learning method only one study that compared gene expression patterns between HCC yielded 83 genes for which expression differed between the two types of with HBV infection (B-type HCC) and HCC with HCV infection HCCs. Expression levels of 31 of these 83 genes were increased in HBV- (C-type HCC; 14), and only a limited number of specimens were associated HCCs, and expression levels of the remaining 52 genes were analyzed.
    [Show full text]
  • Discovery of Screening Biomarkers for Major Depressive Disorder in Remission by Proteomic Approach
    Article Discovery of Screening Biomarkers for Major Depressive Disorder in Remission by Proteomic Approach Hyebin Choi 1, Sora Mun 1, Eun-Jeong Joo 2,3, Kyu Young Lee 2,4, Hee-Gyoo Kang 1,5,* and Jiyeong Lee 6,* 1 Department of Senior Healthcare, Graduate School, Eulji University, Seongnam 13135, Korea; [email protected] (H.C.); [email protected] (S.M.) 2 Department of Neuropsychiatry, School of Medicine, Eulji University, Daejeon 34824, Korea; [email protected] (E.-J.J.); [email protected] (K.Y.L.) 3 Department of Psychiatry, Uijeongbu Eulji Medical Center, Eulji University, Gyeonggi 11759, Korea 4 Department of Psychiatry, Eulji General Hospital, Seoul 01830, Korea 5 Department of Biomedical Laboratory Science, College of Health Science, Eulji University, Seongnam 13135, Korea 6 Department of Biomedical Laboratory Science, College of Health Science, Eulji University, Uijeongbu 11759, Korea * Correspondence: [email protected] (H.-G.K.); [email protected] (J.L.); Tel.: +82-31-740-7315 (H.-G.K.); +82-42-259-1752 (J.L.) Abstract: Major depressive disorder (MDD) is a common disorder involving depressive mood and decreased motivation. Due to its high heterogeneity, novel biomarkers are required to diagnose MDD. In this study, a proteomic method was used to identify a new MDD biomarker. Using sequential window acquisition of all theoretical mass spectra acquisitions and multiple reaction monitoring analysis via mass spectrometry, relative and absolute quantification of proteins in the sera was per- formed. The results of the relative quantitation by sequential window acquisition for all theoretical mass spectra data showed that seven proteins were significantly differently expressed between MDD Citation: Choi, H.; Mun, S.; Joo, E.-J.; Lee, K.Y.; Kang, H.-G.; Lee, J.
    [Show full text]
  • The Structure, Function and Evolution of the Extracellular Matrix: a Systems-Level Analysis
    The Structure, Function and Evolution of the Extracellular Matrix: A Systems-Level Analysis by Graham L. Cromar A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy Department of Molecular Genetics University of Toronto © Copyright by Graham L. Cromar 2014 ii The Structure, Function and Evolution of the Extracellular Matrix: A Systems-Level Analysis Graham L. Cromar Doctor of Philosophy Department of Molecular Genetics University of Toronto 2014 Abstract The extracellular matrix (ECM) is a three-dimensional meshwork of proteins, proteoglycans and polysaccharides imparting structure and mechanical stability to tissues. ECM dysfunction has been implicated in a number of debilitating conditions including cancer, atherosclerosis, asthma, fibrosis and arthritis. Identifying the components that comprise the ECM and understanding how they are organised within the matrix is key to uncovering its role in health and disease. This study defines a rigorous protocol for the rapid categorization of proteins comprising a biological system. Beginning with over 2000 candidate extracellular proteins, 357 core ECM genes and 524 functionally related (non-ECM) genes are identified. A network of high quality protein-protein interactions constructed from these core genes reveals the ECM is organised into biologically relevant functional modules whose components exhibit a mosaic of expression and conservation patterns. This suggests module innovations were widespread and evolved in parallel to convey tissue specific functionality on otherwise broadly expressed modules. Phylogenetic profiles of ECM proteins highlight components restricted and/or expanded in metazoans, vertebrates and mammals, indicating taxon-specific tissue innovations. Modules enriched for medical subject headings illustrate the potential for systems based analyses to predict new functional and disease associations on the basis of network topology.
    [Show full text]
  • Evolution of Gene Regulation in Ruminants Differs Between Evolutionary Breakpoint Regions and Homologous Synteny Blocks
    Downloaded from genome.cshlp.org on September 27, 2021 - Published by Cold Spring Harbor Laboratory Press Research Evolution of gene regulation in ruminants differs between evolutionary breakpoint regions and homologous synteny blocks Marta Farré,1,18 Jaebum Kim,2,18 Anastasia A. Proskuryakova,3,4 Yang Zhang,5 Anastasia I. Kulemzina,3 Qiye Li,6 Yang Zhou,6 Yingqi Xiong,6 Jennifer L. Johnson,7 Polina L. Perelman,3,4 Warren E. Johnson,8,9 Wesley C. Warren,10 Anna V. Kukekova,7 Guojie Zhang,6,11,12 Stephen J. O’Brien,13,14 Oliver A. Ryder,15 Alexander S. Graphodatsky,3,4 Jian Ma,5 Harris A. Lewin,16 and Denis M. Larkin1,17 1Royal Veterinary College, University of London, London NW1 0TU, United Kingdom; 2Department of Biomedical Science and Engineering, Konkuk University, Seoul 05029, Korea; 3Institute of Molecular and Cellular Biology, SB RAS, Novosibirsk 630090, Russia; 4Synthetic Biology Unit, Novosibirsk State University, Novosibirsk 630090, Russia; 5Computational Biology Department, School of Computer Science, Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA; 6China National GeneBank, BGI- Shenzhen, Shenzhen 518083, China; 7Department of Animal Sciences, College of Agricultural, Consumer and Environmental Sciences, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, USA; 8Smithsonian Conservation Biology Institute, National Zoological Park, Front Royal, Virginia 22630, USA; 9Walter Reed Biosystematics Unit, Museum Support Center, Smithsonian Institution, Suitland, Maryland 20746, USA; 10Bond Life Sciences Center, University of Missouri, Columbia, Missouri 63201, USA; 11State Key Laboratory of Genetic Resources and Evolution, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming 650223, China; 12Centre for Social Evolution, Department of Biology, University of Copenhagen, DK-2100 Copenhagen, Denmark; 13Theodosius Dobzhansky Center for Genome Bioinformatics, St.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,662,389 B2 Clark Et Al
    USOO7662389B2 (12) United States Patent (10) Patent No.: US 7,662,389 B2 Clark et al. (45) Date of Patent: Feb. 16, 2010 (54) USE OF SERUM AMYLOIDA GENE IN Cotton et al., Proc. Natl. Acad. Sci. USA 85.4397 (1988): “Reactivity DAGNOSIS AND TREATMENT OF of cytosine and thymine in single-base-pair mismatches with GLAUCOMIA AND IDENTIFICATION OF hydroxylamine and osmium tetroxide and its application to the study ANT-GLAUCOMAAGENTS of mutations'. Cotton, Mutat. Res. 285:125-144 (1993); "Current methods of muta tion detection'. (75) Inventors: Abbot F. Clark, Arlington, TX (US); Croninet al., Human Mutation 7:244-255 (1996); "Cystic Fibrosis Wan-Heng Wang, Grapevine, TX (US); Mutation Detection by Hybridization to Light-Generated DNA Loretta Graves McNatt, Hurst, TX Probe Arrays”. (US) Ermilov et al. (1993); Arkh Patol.; “Senile amyloidosis of the eye as a manifestation of senile cerebral amyloidosis' abstract with article (73) Assignee: Alcon, Inc., Hunenberg (CH) in Russian 55(6):43-45. Furlenato, CJ, and Campa A, Biochem. Biophys. Res. Commun 268:405-408 (2002), “A novel function of serum amyloid A. apotent (*) Notice: Subject to any disclaimer, the term of this stimulus for the release of tumor necrosis factor-alpha, interleukin-1 patent is extended or adjusted under 35 beta, and interleukin-8 by human blood neutrophil”. U.S.C. 154(b) by 130 days. Gasparini et al., Mol. Cell Probes 6:1-7 (1992); "Restriction site generating-polymerase chain reaction (RG-PCR) for the probeless (21) Appl. No.: 11/615.454 detection of hidden genetic variation: application to the study of some common cystic fibrosis mutations'.
    [Show full text]